{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:21:33Z","timestamp":1790824893514,"version":"4.1.0"},"reference-count":143,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002954","name":"University of Milano-Bicocca","doi-asserted-by":"publisher","award":["2021-ATE-0069"],"award-info":[{"award-number":["2021-ATE-0069"]}],"id":[{"id":"10.13039\/501100002954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The role of T-type calcium channels is well established in excitable cells, where they preside over action potential generation, automaticity, and firing. They also contribute to intracellular calcium signaling, cell cycle progression, and cell fate; and, in this sense, they emerge as key regulators also in non-excitable cells. In particular, their expression may be considered a prognostic factor in cancer. Almost all cancer cells express T-type calcium channels to the point that it has been considered a pharmacological target; but, as the drugs used to reduce their expression are not completely selective, several complications develop, especially within the heart. T-type calcium channels are also involved in a specific side effect of several anticancer agents, that act on microtubule transport, increase the expression of the channel, and, thus, the excitability of sensory neurons, and make the patient more sensitive to pain. This review puts into context the relevance of T-type calcium channels in cancer and in chemotherapy side effects, considering also the cardiotoxicity induced by new classes of antineoplastic molecules.<\/jats:p>","DOI":"10.3390\/ijms23179894","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T01:50:51Z","timestamp":1661997051000},"page":"9894","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["T-Type Calcium Channels: A Mixed Blessing"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0563-8041","authenticated-orcid":false,"given":"Dario","family":"Melgari","sequence":"first","affiliation":[{"name":"Institute of Molecular and Translational Cardiology, IRCCS Policlinico San Donato, Piazza Malan 2, 20097 San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-989X","authenticated-orcid":false,"given":"Anthony","family":"Frosio","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Cardiology, IRCCS Policlinico San Donato, Piazza Malan 2, 20097 San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Calamaio","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Cardiology, IRCCS Policlinico San Donato, Piazza Malan 2, 20097 San Donato Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-8492","authenticated-orcid":false,"given":"Gaia A.","family":"Marzi","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore, 48, 20900 Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pappone","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Cardiology, IRCCS Policlinico San Donato, Piazza Malan 2, 20097 San Donato Milanese, Italy"},{"name":"Arrhythmology Department, IRCCS Policlinico San Donato, Piazza Malan 2, 20097 San Donato Milanese, Italy"},{"name":"Faculty of Medicine and Surgery, University Vita-Salute San Raffaele, Via Olgettina 58, 20097 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7411-9069","authenticated-orcid":false,"given":"Ilaria","family":"Rivolta","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Cardiology, IRCCS Policlinico San Donato, Piazza Malan 2, 20097 San Donato Milanese, Italy"},{"name":"School of Medicine and Surgery, University of Milano-Bicocca, Via Cadore, 48, 20900 Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1254\/jphs.FMJ05002X2","article-title":"Pathophysiological Significance of T-type Ca2+ Channels: Properties and Functional Roles of T-type Ca2+ Channels in Cardiac Pacemaking","volume":"99","author":"Ono","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1152\/physrev.00018.2002","article-title":"Molecular Physiology of Low-Voltage-Activated T-type Calcium Channels","volume":"83","year":"2003","journal-title":"Physiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/187152706779025490","article-title":"The role of T-type calcium channels in peripheral and central pain processing","volume":"5","author":"Todorovic","year":"2006","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7627","DOI":"10.1073\/pnas.97.13.7627","article-title":"T-type \u03b11H Ca2+ channels are involved in Ca2+ signaling during terminal differentiation (fusion) of human myoblasts","volume":"97","author":"Bijlenga","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.ph.58.030196.001553","article-title":"Low-threshold calcium currents in central nervous system neurons","volume":"58","author":"Huguenard","year":"1996","journal-title":"Annu. Rev. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"R227","DOI":"10.1152\/ajpregu.00276.2014","article-title":"Functional importance of T-type voltage-gated calcium channels in the cardiovascular and renal system: News from the world of knockout mice","volume":"308","author":"Hansen","year":"2015","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00424-014-1489-z","article-title":"T-type channel-mediated neurotransmitter release","volume":"466","author":"Carbone","year":"2014","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/01.RES.83.1.103","article-title":"Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family","volume":"83","author":"Cribbs","year":"1998","journal-title":"Circ. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/36110","article-title":"Molecular characterization of a neuronal low-voltage-activated T-type calcium channel","volume":"391","author":"Cribbs","year":"1998","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1523\/JNEUROSCI.19-06-01912.1999","article-title":"Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family","volume":"19","author":"Lee","year":"1999","journal-title":"J. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biocel.2019.01.008","article-title":"T-type calcium channels: From molecule to therapeutic opportunities","volume":"108","author":"Weiss","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Shah, K., Seeley, S., Schulz, C., Fisher, J., and Rao, S.G. (2022). Calcium Channels in the Heart: Disease States and Drugs. Cells, 11.","DOI":"10.3390\/cells11060943"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1046\/j.1460-9568.1999.00849.x","article-title":"Comparison of the Ca2+ currents induced by expression of three cloned alpha1 subunits, alpha1G, alpha1H and alpha1I, of low-voltage-activated T-type Ca2+ channels","volume":"11","author":"Lee","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1016\/S0006-3495(99)77134-1","article-title":"Nickel block of three cloned T-type calcium channels: Low concentrations selectively block \u03b11H","volume":"77","author":"Lee","year":"1999","journal-title":"Biophys. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00424-020-02429-7","article-title":"Neuronal Cav3 channelopathies: Recent progress and perspectives","volume":"472","author":"Lory","year":"2020","journal-title":"Pfl\u00fcgers Arch.-Eur. J. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/bph.13906","article-title":"Recent advances in the development of T-type calcium channel blockers for pain intervention","volume":"175","author":"Snutch","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00424-014-1454-x","article-title":"T-type calcium channel blockers as neuroprotective agents","volume":"466","author":"Kopecky","year":"2014","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bcp.2011.10.019","article-title":"A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats","volume":"83","author":"Scott","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/13543776.2018.1541982","article-title":"T-type calcium channel blockers: A patent review (2012\u20132018)","volume":"28","author":"Nam","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/acschemneuro.9b00031","article-title":"T-Type Channel Druggability at a Crossroads","volume":"10","author":"Weiss","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/jpet.108.145672","article-title":"Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: Block by antihypertensives, antiarrhythmics, and their analogs","volume":"328","author":"Vitko","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1523\/JNEUROSCI.22-02-00396.2002","article-title":"Differential inhibition of T-type calcium channels by neuroleptics","volume":"22","author":"Santi","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1124\/mol.105.020842","article-title":"T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine","volume":"69","author":"Traboulsie","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1523\/JNEUROSCI.22-06-02023.2002","article-title":"Kurtoxin, a gating modifier of neuronal high- and low-threshold ca channels","volume":"22","author":"Sidach","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1016\/j.bbamem.2015.03.034","article-title":"Targeting ion channels for cancer therapy by repurposing the approved drugs","volume":"1848","author":"Kale","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1016\/j.bmcl.2006.07.046","article-title":"Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers","volume":"16","author":"Lee","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_27","first-page":"302","article-title":"Mibefradil block of cloned T-type calcium channels","volume":"295","author":"Martin","year":"2000","journal-title":"J Pharm. Exp. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6606-7-36","article-title":"Block of T-type calcium channels by protoxins I and II","volume":"7","author":"Bladen","year":"2014","journal-title":"Mol. Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2007.05.011","article-title":"Trazodone inhibits T-type calcium channels","volume":"53","author":"Kraus","year":"2007","journal-title":"Neuropharmacology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1124\/mol.110.069492","article-title":"Verapamil block of T-type calcium channels","volume":"79","author":"Bergson","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.yjmcc.2009.08.021","article-title":"Cardiac T-type Ca2+ channels in the heart","volume":"48","author":"Ono","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ceca.2006.04.025","article-title":"Role of T-type Ca2+ channels in the heart","volume":"40","author":"Vassort","year":"2006","journal-title":"Cell Calcium"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Senatore, A., and Spafford, J.D. (2012). Gene transcription and splicing of T-type channels are evolutionarily-conserved strategies for regulating channel expression and gating. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0037409"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1006\/jmcc.2002.1535","article-title":"Functional and molecular characterization of a T-type Ca(2+) channel during fetal and postnatal rat heart development","volume":"34","author":"Ferron","year":"2002","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"H2257","DOI":"10.1152\/ajpheart.01043.2003","article-title":"Cav3.2 subunit underlies the functional T-type Ca2+ channel in murine hearts during the embryonic period","volume":"286","author":"Niwa","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"I11","DOI":"10.1007\/s003950200023","article-title":"Voltage-gated Ca2+ currents in the human pathophysiologic heart: A review","volume":"97","author":"Benitah","year":"2002","journal-title":"Basic Res. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6090","DOI":"10.1074\/jbc.275.9.6090","article-title":"Molecular and Functional Properties of the Human \u03b11G Subunit That Forms T-type Calcium Channels","volume":"275","author":"Monteil","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.108.804369","article-title":"Molecular architecture of the human sinus node: Insights into the function of the cardiac pacemaker","volume":"119","author":"Chandler","year":"2009","journal-title":"Circulation"},{"key":"ref_39","first-page":"74","article-title":"Effects of the T-type calcium channel blockade with oral mibefradil on the electrophysiologic properties of the human heart","volume":"7","author":"Koza","year":"2001","journal-title":"Med. Sci. Monit."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/01.RES.73.4.777","article-title":"T-type Ca2 current is expressed in hypertrophied adult feline left ventricular myocytes","volume":"73","author":"Nuss","year":"1993","journal-title":"Circ. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1006\/jmcc.1999.0998","article-title":"Expression of T-type Ca2 Channels in Ventricular Cells from Hypertrophied Rat Hearts","volume":"31","author":"Martinez","year":"1999","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/CIRCRESAHA.108.184051","article-title":"The CaV3.2 T-Type Ca2+ Channel Is Required for Pressure Overload-Induced Cardiac Hypertrophy in Mice","volume":"104","author":"Chiang","year":"2009","journal-title":"Circ. Res."},{"key":"ref_43","first-page":"184","article-title":"Modulation of calcium-currents by capsaicin in a subpopulation of sensory neurones of guinea pig","volume":"339","author":"Petersen","year":"1989","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fncel.2019.00271","article-title":"Human Dorsal Root Ganglia","volume":"13","author":"Haberberger","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0896-6273(01)00338-5","article-title":"Redox modulation of T-type calcium channels in rat peripheral nociceptors","volume":"31","author":"Todorovic","year":"2001","journal-title":"Neuron"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.emboj.7600515","article-title":"Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception","volume":"24","author":"Bourinet","year":"2005","journal-title":"EMBO J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8766","DOI":"10.1523\/JNEUROSCI.2527-05.2005","article-title":"The endogenous redox agent L-cysteine induces T-type Ca2+ channel-dependent sensitization of a novel subpopulation of rat peripheral nociceptors","volume":"25","author":"Nelson","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trsl.2021.01.002","article-title":"Targeting T-type\/CaV3.2 channels for chronic pain","volume":"234","author":"Cai","year":"2021","journal-title":"Transl. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1744806919836569","DOI":"10.1177\/1744806919836569","article-title":"Nerve injury elevates functional Cav3.2 channels in superficial spinal dorsal horn","volume":"15","author":"Feng","year":"2019","journal-title":"Mol. Pain"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1523\/JNEUROSCI.0181-19.2019","article-title":"Cdk5-Dependent Phosphorylation of CaV3.2 T-Type Channels: Possible Role in Nerve Ligation-Induced Neuropathic Allodynia and the Compound Action Potential in Primary Afferent C Fibers","volume":"40","author":"Gomez","year":"2020","journal-title":"J. Neurosci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.neuron.2014.07.036","article-title":"The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity","volume":"83","author":"Gadotti","year":"2014","journal-title":"Neuron"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"173587","DOI":"10.1016\/j.ejphar.2020.173587","article-title":"Cav3.2 overexpression in L4 dorsal root ganglion neurons after L5 spinal nerve cutting involves Egr-1, USP5 and HMGB1 in rats: An emerging signaling pathway for neuropathic pain","volume":"888","author":"Tomita","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/bja\/aex229","article-title":"Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): A narrative review","volume":"119","author":"Flatters","year":"2017","journal-title":"Br. J. Anaesth."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zajaczkowsk\u0105, R., Kocot-K\u0119pska, M., Leppert, W., Wrzosek, A., Mika, J., and Wordliczek, J. (2019). Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061451"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"113121","DOI":"10.1016\/j.expneurol.2019.113121","article-title":"Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems","volume":"324","author":"Staff","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2018-0590","article-title":"Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer","volume":"24","author":"Nyrop","year":"2019","journal-title":"Oncologist"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/j.pain.0000000000000774","article-title":"Dorsal root ganglion neurons become hyperexcitable and increase expression of voltage-gated T-type calcium channels (Cav3.2) in paclitaxel-induced peripheral neuropathy","volume":"158","author":"Li","year":"2017","journal-title":"Pain"},{"key":"ref_58","first-page":"2615","article-title":"Proteasome inhibitors: A novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1535-7163.MCT-11-0745","article-title":"Bortezomib: Understanding the Mechanism of Action","volume":"10","author":"Piperdi","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jprot.2013.02.024","article-title":"Non-enzymatic post-translational protein modifications and proteostasis network deregulation in carcinogenesis","volume":"92","author":"Trougakos","year":"2013","journal-title":"J. Proteom."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","article-title":"Bortezomib-induced peripheral neurotoxicity: An update","volume":"88","author":"Argyriou","year":"2014","journal-title":"Arch. Toxicol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Pancheri, E., Guglielmi, V., Wilczynski, G.M., Malatesta, M., Tonin, P., Tomelleri, G., Nowis, D., and Vattemi, G. (2020). Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. Cancers, 12.","DOI":"10.3390\/cancers12092540"},{"key":"ref_63","first-page":"841","article-title":"PS-341, a Novel Proteasome Inhibitor, Induces Bcl-2 Phosphorylation and Cleavage in Association with G2-M Phase Arrest and Apoptosis","volume":"1","author":"Ling","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.expneurol.2010.02.006","article-title":"Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice","volume":"223","author":"Bruna","year":"2010","journal-title":"Exp. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tox.2018.12.003","article-title":"Critical role of Cav3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice","volume":"413","author":"Tomita","year":"2019","journal-title":"Toxicology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"17802","DOI":"10.1038\/s41598-017-17596-4","article-title":"Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: A link to clinical adverse events","volume":"7","author":"Tsakiri","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2141.2007.06659.x","article-title":"Unexpected cardiotoxicity in haematological bortezomib treated patients","volume":"138","author":"Orciuolo","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/fcp.12039","article-title":"Bortezomib and heart failure: Case-report and review of the French Pharmacovigilance database","volume":"28","author":"Honton","year":"2014","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cardiores.2003.09.033","article-title":"The ubiquitin--proteasome system in cardiovascular diseases\u2014A hypothesis extended","volume":"61","author":"Herrmann","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V","article-title":"Modes of regulation of ubiquitin-mediated protein degradation","volume":"182","author":"Kornitzer","year":"2000","journal-title":"J. Cell. Physiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/(SICI)1097-4644(2000)77:34+<40::AID-JCB9>3.0.CO;2-6","article-title":"The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications","volume":"77","author":"Ciechanover","year":"2000","journal-title":"J. Cell. Biochem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrm2673","article-title":"Ubiquitin-like protein activation by E1 enzymes: The apex for downstream signalling pathways","volume":"10","author":"Schulman","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/378416a0","article-title":"A protein catalytic framework with an N-terminal nucleophile is capable of self-activation","volume":"378","author":"Brannigan","year":"1995","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0969-2126(02)00748-7","article-title":"The structure of the mammalian 20S proteasome at 2.75 \u00c5resolution","volume":"10","author":"Unno","year":"2002","journal-title":"Structure"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S Proteasome: A Molecular Machine Designed for Controlled Proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2016.12.007","article-title":"Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect","volume":"103","author":"Kaplan","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bbrc.2005.09.053","article-title":"Evidence for proteasomal degradation of Kv1.5 channel protein","volume":"337","author":"Kato","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_81","first-page":"5325","article-title":"Downregulation of the HERG (KCNH2) K+ channel by ceramide: Evidence for ubiquitin-mediated lysosomal degradation","volume":"118","author":"Chapman","year":"2005","journal-title":"J. Cell Mol. Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.cardiores.2005.12.021","article-title":"The ubiquitin--proteasome system: Focus on the heart","volume":"70","author":"Zolk","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"19419","DOI":"10.1074\/jbc.M502327200","article-title":"Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway","volume":"280","author":"Gong","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Mihic, A., Chauhan, V.S., Gao, X., Oudit, G.Y., and Tsushima, R.G. (2011). Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018273"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"19976","DOI":"10.1038\/srep19976","article-title":"Schizophrenia-Associated hERG channel Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued Through Proteasome Inhibition for High Throughput Screening","volume":"6","author":"Calcaterra","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.redox.2018.08.018","article-title":"Suppression of hERG K+ current and cardiac action potential prolongation by 4-hydroxynonenal via dual mechanisms","volume":"19","author":"Choi","year":"2018","journal-title":"Redox Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1161\/01.RES.0000136816.05109.89","article-title":"Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2 mediated ubiquitination","volume":"95","author":"Rougier","year":"2004","journal-title":"Circ. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1476-5381.2009.00174.x","article-title":"Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity","volume":"157","author":"Kang","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fphys.2013.00051","article-title":"Proteasome inhibitor (MG132) rescues Nav1.5 protein content and the cardiac sodium current in dystrophin-deficient mdx5cv mice","volume":"4","author":"Rougier","year":"2013","journal-title":"Front. Physiol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Morais, E.R., Oliveira, K.C., de Paula, R.G., Ornelas, A.M.M., Moreira, \u00c9.B.C., Badoco, F.R., Magalh\u00e3es, L.G., Verjovski-Almeida, S., and Rodrigues, V. (2017). Effects of proteasome inhibitor MG-132 on the parasite Schistosoma mansoni. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0184192"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pharmthera.2016.09.009","article-title":"Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?","volume":"168","author":"Magdy","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_92","first-page":"149","article-title":"The cardiotoxicity of chemotherapy: New prospects for an old problem","volume":"40","author":"Miolo","year":"2006","journal-title":"Radiol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"847012","DOI":"10.3389\/fcvm.2022.847012","article-title":"Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection","volume":"9","author":"Morelli","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_94","first-page":"161","article-title":"Cardiotoxicity and oncological treatments","volume":"111","author":"Schlitt","year":"2014","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1470-2045(17)30613-7","article-title":"Carfilzomib versus bortezomib: No longer an ENDEAVOR","volume":"18","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"64","DOI":"10.15420\/ecr.2017:17:2","article-title":"Cardio-oncology: A focus on cardiotoxicity","volume":"13","author":"Koutsoukis","year":"2018","journal-title":"Eur. Cardiol. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.2353\/ajpath.2010.090690","article-title":"Cardiotoxicity of the anticancer therapeutic agent bortezomib","volume":"176","author":"Nowis","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","article-title":"Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib","volume":"17","author":"Hasinoff","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/cvr\/cvq217","article-title":"Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts","volume":"88","author":"Tang","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.yjmcc.2013.10.008","article-title":"Regulation of cardiac proteasomes by ubiquitination, SUMOylation, and beyond","volume":"71","author":"Cui","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCRESAHA.112.300521","article-title":"Role of the ubiquitin proteasome system in the heart","volume":"112","author":"Pagan","year":"2013","journal-title":"Circ. Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF-Inhibitor Associated Hypertension and Vascular Disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","article-title":"Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review","volume":"77","author":"Rao","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncology"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Antal, L., and Martin-Caraballo, M. (2019). T-type Calcium Channels in Cancer. Cancers, 11.","DOI":"10.3390\/cancers11020134"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-16-2347","article-title":"Targetable T-type Calcium Channels Drive Glioblastoma","volume":"77","author":"Zhang","year":"2017","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1158\/0008-5472.CAN-18-1924","article-title":"T-Type Ca v 3.1 Channels Mediate Progression and Chemotherapeutic Resistance in Glioblastoma","volume":"79","author":"Visa","year":"2019","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Maklad, A., Sedeeq, M., Milevskiy, M.J.G., and Azimi, I. (2021). Calcium Signalling in Medulloblastoma: An In Silico Analysis of the Expression of Calcium Regulating Genes in Patient Samples. Genes, 12.","DOI":"10.3390\/genes12091329"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/pros.23879","article-title":"T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells","volume":"79","author":"Silvestri","year":"2019","journal-title":"Prostate"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"10824","DOI":"10.1074\/jbc.M108754200","article-title":"Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells","volume":"277","author":"Mariot","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.canlet.2008.03.032","article-title":"Selective blockade of T-type Ca2+ channels suppresses human breast cancer cell proliferation","volume":"267","author":"Taylor","year":"2008","journal-title":"Cancer Lett."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Barcel\u00f3, C., Sis\u00f3, P., Maiques, O., de la Rosa, I., Mart\u00ed, R.M., and Maci\u00e0, A. (2020). T-Type Calcium Channels: A Potential Novel Target in Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12020391"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10735-020-09937-x","article-title":"Overexpression of T-type calcium channel Cav3.1 in oral squamous cell carcinoma: Association with proliferation and anti-apoptotic activity","volume":"52","author":"Li","year":"2021","journal-title":"J. Mol. Histol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fonc.2019.00124","article-title":"The emerging role of voltage-gated sodium channels in tumor biology","volume":"9","author":"Mao","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fncel.2015.00086","article-title":"Cancer as a channelopathy: Ion channels and pumps in tumor development and progression","volume":"9","author":"Litan","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/19336950.2019.1666455","article-title":"Voltage gated sodium channels in cancer and their potential mechanisms of action","volume":"13","author":"Angus","year":"2019","journal-title":"Channels"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.ceca.2020.102251","article-title":"Insights and perspectives on calcium channel functions in the cockpit of cancerous space invaders","volume":"90","author":"Destaing","year":"2020","journal-title":"Cell Calcium"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.molmed.2019.03.001","article-title":"The Hard-To-Close Window of T-Type Calcium Channels","volume":"25","author":"Visa","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bcp.2006.12.011","article-title":"G1 cell cycle arrest by amlodipine, a dihydropyridine Ca2+ channel blocker, in human epidermoid carcinoma A431 cells","volume":"73","author":"Yoshida","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"ref_120","first-page":"1090","article-title":"Selective uveal melanoma inhibition with calcium channel blockade","volume":"55","author":"Shaughnessy","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"105152","DOI":"10.1016\/j.tiv.2021.105152","article-title":"Calcium channel blockers lercanidipine and amlodipine inhibit YY1\/ERK\/TGF-\u03b2 mediated transcription and sensitize the gastric cancer cells to doxorubicin","volume":"74","author":"Panneerpandian","year":"2021","journal-title":"Toxicol. Vitr."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1073\/pnas.2200143119","article-title":"Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer","volume":"119","author":"Principe","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/CAD.0000000000001273","article-title":"Amlodipine improves the outcomes of regorafenib in metastatic colorectal cancer","volume":"33","author":"Karaman","year":"2022","journal-title":"Anticancer. Drugs"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s11033-019-04706-w","article-title":"Vincristine combination with Ca2+ channel blocker increase antitumor effects","volume":"46","author":"Taghizadehghalehjoughi","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"105262","DOI":"10.1016\/j.bioorg.2021.105262","article-title":"Structural optimization, synthesis and in vitro synergistic anticancer activities of combinations of new N3-substituted dihydropyrimidine calcium channel blockers with cisplatin and etoposide","volume":"115","author":"Teleb","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/0008-5472.CAN-17-3061","article-title":"T-type Ca2+ Channels: T for targetable","volume":"78","author":"Sallan","year":"2018","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7123","DOI":"10.1016\/j.bmcl.2012.09.076","article-title":"T-type Ca2+ channel blocker, KYS05047 induces G1 phase cell cycle arrest by decreasing intracellular Ca2+ levels in human lung adenocarcinoma A549 cells","volume":"22","author":"Rim","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_128","unstructured":"Garrido-Laguna, I., Tan, A., Villarroel, M., Rajeshkumar, N., Rubio-Viqueira, B., Gray, L., and Hidalgo, M. (2008, January 22\u201325). Activity of the T-type calcium channel antagonist Mibefradil in pancreatic cancer xenografts. Proceedings of the Third AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development, Philadelphia, PA, USA."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-15-0456","article-title":"T-type Ca2+ channel inhibition sensitizes ovarian cancer to carboplatin","volume":"15","author":"Dziegielewska","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4236\/jct.2013.47A006","article-title":"Exploiting MCF-7 Cells\u2019 Calcium Dependence with Interlaced Therapy","volume":"4","author":"Pottle","year":"2013","journal-title":"J. Cancer Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/neuonc\/nox020","article-title":"Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas","volume":"19","author":"Holdhoff","year":"2017","journal-title":"Neuro-Oncology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00109-014-1235-1","article-title":"NNC 55-0396, a T-type Ca2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1\u03b1 signal transduction","volume":"93","author":"Kim","year":"2015","journal-title":"J. Mol. Med."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Tuan, N.M., and Lee, C.H. (2019). Penfluridol as a Candidate of Drug Repurposing for Anticancer Agent. Molecules, 24.","DOI":"10.3390\/molecules24203659"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/01.RES.75.1.144","article-title":"Selective inhibition of T-type Ca2+ channels by Ro 40-5967","volume":"75","author":"Mishra","year":"1994","journal-title":"Circ. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1007\/s12035-022-02771-0","article-title":"T-Type Calcium Channel Inhibitors Induce Apoptosis in Medulloblastoma Cells Associated with Altered Metabolic Activity","volume":"59","author":"Sedeeq","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"188364","DOI":"10.1016\/j.bbcan.2020.188364","article-title":"The rise of T-type channels in melanoma progression and chemotherapeutic resistance","volume":"1873","author":"Alza","year":"2020","journal-title":"Biochim. Biophys. Acta-Rev. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/107424840100600306","article-title":"Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes","volume":"6","author":"Drolet","year":"2001","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(95)00691-5","article-title":"Mechanism of L- and T-type Ca2+ channel blockade by flunarizine in ventricular myocytes of the guinea-pig","volume":"296","author":"Tytgat","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1021\/acsptsci.1c00079","article-title":"Cyclic Peptides as T-Type Calcium Channel Blockers: Characterization and Molecular Mapping of the Binding Site","volume":"4","author":"Depuydt","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_140","first-page":"996","article-title":"Adjuvant role of a T-type calcium channel blocker, TTA-A2, in lung cancer treatment with paclitaxel","volume":"4","author":"Kumari","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-018-4970-0","article-title":"T-Type voltage gated calcium channels: A target in breast cancer?","volume":"173","author":"Bhargava","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Meregalli, C., Maricich, Y., Cavaletti, G., Canta, A., Carozzi, V.A., Chiorazzi, A., Newbold, E., Marmiroli, P., Ceresa, C., and Diani, A. (2021). Reversal of bortezomib-induced neurotoxicity by suvecaltamide, a selective T-type ca-channel modulator, in preclinical models. Cancers, 13.","DOI":"10.3390\/cancers13195013"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"102610","DOI":"10.1016\/j.ceca.2022.102610","article-title":"T-type channels in cancer cells: Driving in reverse","volume":"105","author":"Alza","year":"2022","journal-title":"Cell Calcium"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/9894\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:20:49Z","timestamp":1760142049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/17\/9894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":143,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijms23179894"],"URL":"https:\/\/doi.org\/10.3390\/ijms23179894","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]}}}